期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 131, 期 3, 页码 338-340出版社
WILEY
DOI: 10.1111/j.1365-2141.2005.05777.x
关键词
rituximab; chlorambucil; mantle cell lymphoma; B-cell non-Hodgkin lymphoma; immuno-chemotherapy
类别
We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据